美国医疗补助计划负责人：将在未来30天内就药品价格问题与制药公司接洽。

Core Insights - The head of the U.S. Medicaid program announced plans to engage with pharmaceutical companies regarding drug pricing issues within the next 30 days [1] Group 1 - The U.S. Medicaid program is taking proactive steps to address concerns related to drug prices [1] - The engagement with pharmaceutical companies indicates a potential shift in policy or negotiation strategies aimed at controlling medication costs [1] - This initiative may impact the pharmaceutical industry significantly, as it could lead to changes in pricing structures and reimbursement rates [1]